ReviewSkin health and disease2026
Comparison of narrowband ultraviolet B with psoralen plus ultraviolet A phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis.
Review in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The most prevalent cutaneous T-cell lymphoma is mycosis fungoides (MF), managed in early stages with psoralen plus ultraviolet A (PUVA) or narrowband ultraviolet B (NB-UVB) phototherapy. Objectives: To evaluate the therapeutic effectiveness and side effect profiles of PUVA vs. NB-UVB in patients with early-stage MF. Method: A systematic review was conducted, incorporating data from nine studies sourced from PubMed, Cochrane and Google Scholar. Eligible studies were those that simultaneously evaluated PUVA and NB-UVB, enrolling at least 10 adult participants per group with histologically confirmed early-stage (IA-IIA) MF and reported treatment outcomes. Exclusions were advanced disease, paediatric patients, noncomparative or nonrelevant treatments, small sample sizes or lack of outcome data. No language restrictions were applied. Key outcomes included any response, complete response, partial response, treatment failure, relapse-free interval and adverse effects. Results: A total of 923 patients (age range 33-71 years; 52.5% men) were included: 556 treated with PUVA and 367 with NB-UVB. Any response was seen in 90.5% of those treated with PUVA vs. 88.3% of patients who received NB-UVB [odds ratio (OR) 1.18, 95% confidence interval (CI) 0.73-1.90; Conclusions: Both PUVA and NB-UVB are effective, but PUVA may be preferred when sustained remission is the primary therapeutic goal.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.